This Article Full Text Full Text (PDF) All Versions of this Article: 32/4/924    most recent 09031936.00167407v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Wu, S-G. Articles by Yang, P-C. Search for Related Content PubMed PubMed Citation Articles by Wu, S-G. Articles by Yang, P-C.

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

¹ Depts of Internal Medicine, ³ Pathology, ⁴ Oncology, ⁵ Surgery, National Taiwan University Hospital, Taipei, and ² Division of Critical Care Medicine, Dept of Emergency and Critical Care Medicine, Lotung Poh-Ai Hospital, Yi-Lan, Taiwan.

CORRESPONDENCE: J-Y. Shih, Dept of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. Fax: 886 223582867. E-mail: jyshih{at}ntu.edu.tw

Keywords: Epidermal growth factor receptor, lung cancer, mutation, pleural effusion

Received: December 11, 2007
Accepted May 13, 2008

Malignant pleural effusions (MPEs) are often observed in lung cancer, especially adenocarcinoma. Epidermal growth factor receptor (EGFR) gene mutations are usually detected in lung adenocarcinoma. The purpose of the present study was to investigate the EGFR mutation rate in MPEs of lung adenocarcinoma.

Between June 2005 and December 2006, 136 MPEs from lung adenocarcinoma were collected for EGFR mutation detection. In addition, between April 2001 and November 2004, 91 surgically resected specimens of lung adenocarcinoma from patients without MPEs were assessed for EGFR mutation.

The EGFR mutation rate was significantly higher in the patients with MPEs than in the patients without (68.4% versus 50.5%). The EGFR mutation rate in patients with MPEs was not associated with sex, smoking history, age or cancer stage. By multivariate analysis, an age of <65 yrs, never smoking, Eastern Cooperative Oncology Group performance status 0–1, and EGFR mutation were significantly associated with a longer overall survival for lung adenocarcinoma patients with MPEs.

The patients with malignant pleural effusions related to lung adenocarcinoma had a higher epidermal growth factor receptor gene mutation rate than the patients from whom surgically resected specimens were taken. Epidermal growth factor receptor tyrosine kinase inhibitors may be the treatment of choice for lung adenocarcinoma with malignant pleural effusions in east Asia.

This article has been cited by other articles:

				A Fassina, A Gazziero, D Zardo, M Corradin, E Aldighieri, and G P Rossi Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis J. Clin. Pathol., December 1, 2009; 62(12): 1096 - 1102. [Abstract] [Full Text] [PDF]

				S.-G. Wu, Y.-L. Chang, Y.-C. Hsu, J.-Y. Wu, C.-H. Yang, C.-J. Yu, M.-F. Tsai, J.-Y. Shih, and P.-C. Yang Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern Oncologist, December 1, 2008; 13(12): 1276 - 1284. [Abstract] [Full Text] [PDF]